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limbic afferents.7 Furthermore, experiences of DBS in man also
suggest a persisting modulation of synaptic plasticity,2 as
indicated by a lasting abstinence- sustaining effect of NAcc DBS
even after explantation of the stimulation device. On the basis of
these ﬁndings, we hypothesize that NAcc DBS facilitates heroin
and methadone abstinence by promoting neuroplastic changes in
dopaminergic neurons.
It remains unclear whether the observed beneﬁcial effects
allow a generalization to other forms of substance addictions.
However, the fact that the patients’ comorbid drug consumption
did not decline challenges this view. The interpretation of this
circumstance in terms of a cross addiction, developing because
heroin is no longer available, is also unlikely as the patients did not
report increased craving for other psychotropic substances.
From a socio behavioral perspective, the application of DBS
could have initially led to a heightened motivation to abstain from
drugs. However, the disappointing awareness of persisting private
and occupational strains in combination with lacking alternative
problem solving strategies might account for the ongoing
comorbid drug consume. Patient 2 for example, reported to
consume amphetamines mainly to keep her weight in balance.
Remaining psychosocial difﬁculties might likewise explain the
renewed decrease of self-perceived quality of life (Modular System
for Quality of Life (MSQoL) in patient 2, thereby underlining the
importance of psychotherapy accompanying DBS in mental
disorders to foster the acquisition of alternative behavioral
strategies.8
Although the achieved abstinence from heroin in our patients is
highly promising, clinical studies with larger samples (as the
clinical trial that is to follow) are needed to further support our
hypothesis, and to evaluate accumbal DBS as a cost effective
treatment option9 for otherwise treatment resistant drug
addiction. Herein, emphasis must be placed on the patients’
pattern of comorbid drug consumption.
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The microbiota–gut–brain axis is an emerging concept in modern
medicine informed by the ability of gut microbiota to alter
brain and behaviour.1 Although some clinical studies have
revealed altered gut microbiota composition in patients with
neurodevelopmental disorders such as autism,2,3 the speciﬁc
Ba
se
lin
e
3 
m
on
th
s
12
 m
on
th
s
6 
m
on
th
s
23
 m
on
th
s
(of
f)
24
 m
on
th
s 0
80
60
40
20
10
50
40
30
20
0
BDI II
HAMA
VAS
Patient 1 (33year male),
Patient 2 (31year female)
MSQoL 1.7
Figure 1. Graphical display of ratings of general quality of life
(Modular System for the assessment of Quality of Life subscale 1.710)
(bars), mood (Beck Depression Inventory (BDI)), anxiety (Hamilton
Anxiety Scale (HAMA)) and craving (VAS) (dashed and solid line)
over a 2 and 1 year period of stimulation for patient 1 and 2, res-
pectively. (Shortly before his 2 years follow-up examination, patient
1 reported a significant increase of alcohol and amphetamine
consumption, accompanied by an increase of BDI and HAMA values,
and an abatement of quality of life. However, an exchange of the
battery was followed by a recovery of his psychiatric symptoms. We
speculate that unchanged craving might be related to persisting
synaptic plasticity2). (Funded by DFG (German Research Foundation)
KFO 219, Else Kro¨ner-Fresenius-Stiftung and BMBF (German Federal
Ministry of Education and Research (01KN1106)).
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contributions of microbiota in early life to the development and
programming of the various facets of social behaviour has not
been investigated.
Germ-free (GF) mice have been critical in assessing the role of
microbiota in all aspects of physiology. Indeed, recent studies
in GF mice report increases in neuroendocrine responses to stress,4,5
altered neurotrophin levels in the hippocampus and amygdala,5–7
reduced anxiety5–7 and non-spatial memory,8 and altered
monoamine neurotransmitter levels in the brain.5,6 Interestingly,
many of the deﬁcits are speciﬁc to males4 in which there are higher
incidence rates of neurodevelopmental disorders relative to females.
Here, we examined the effects of GF rearing conditions through
early life and adolescence on social behaviour in adulthood.
Mice, like humans, are a social species and have a natural
propensity to seek out the security and pleasure afforded by stable
social scenarios. Social motivation and preference for social novelty
in mice can be assessed in the three-chambered sociability test.9
Our initial ﬁndings in this test revealed signiﬁcant social
impairments in GF mice, particularly in males, as indicated by a
lack of the normal preference for time spent in a chamber
containing a mouse versus the alternative empty chamber
(GF chamber interaction: F(1,57)¼ 5.35, Po0.05; Supplementary
Figures 1a–c). This was accompanied by reduced preference for
novel social situations, where GF mice did not demonstrate the
normal increase in time spent investigating a novel over a familiar
mouse, which resembles social cognition deﬁcits observed in
patients with neurodevelopmental disorders (GF chamber inter-
action: F(1,57)¼ 5.86, Po0.01; Supplementary Figures 1d–f).
To substantiate these results and to assess the capacity for post-
weaning bacterial colonisation of the GF gut (GFC) to reverse the
observed social deﬁcits, we repeated the test in a different male
cohort. As expected, GF mice exhibited robust deﬁcits including
social avoidance (GF chamber interaction: F(1,20)¼ 12.41,
Po0.001; Figures 1a–c), and diminished preference for social
novelty relative to conventionally colonised (CC) mice (GF
chamber interaction: F(1,20)¼ 4.45, Po0.05; Figures 1d–f). These
effects were not inﬂuenced by changes in general locomotor
activity, as any decrease in chamber entries was speciﬁc to the social
chamber (Supplementary Figure 2). Intriguingly, whereas GFC
reversed the observed social avoidance, it had no effect on social
cognition impairments. This indicates that although the effects of GF
rearing on the latter behaviour are permanently established in the
pre-weaning period, the development of social avoidance in GF
mice is more amenable to microbial-based interventions in later life.
In addition to symptoms of reduced social motivation, children
with autism exhibit poor social and communication skills and
repetitive behaviours. To establish whether the degree of
information transfer during social interaction is disrupted in GF
mice, performance in the social transmission of food preference
test was assessed. GF mice spent a decreased proportion of
time engaged in social investigation (F(2,20)¼ 7.51, Po0.005;
Figure 1g) and substantially greater proportion of time engaged in
repetitive self-grooming behaviour (F(2,20)¼ 11.91, Po0.001;
Figure 1h) during social interaction. These behaviours were
normalised following GF bacterial colonisation, conﬁrming the
involvement of microbiota in modulation of these behaviours.
However, despite the reduction in social investigation times, the
quality of information transfer during the interaction was not
affected in GF mice, as they displayed normal preference for the
novel food (food to which cage-mate was exposed prior to social
interaction) in the subsequent food choice test conducted
immediately after the social interaction and 24 h later (Figures 1i
and j), indicating that the ability to process information per se
during social interaction is not affected in GF mice.
This study shows for, what is to our knowledge, the ﬁrst time
that microbiota are crucial for the programming and presentation
of distinct normal social behaviours, including social motivation
and preference for social novelty, while also being important
regulators of repetitive behaviours. Given that these facets of
behaviour are impaired in neurodevelopmental disorders such as
schizophrenia and autism10 and with a similar male preponderance,
these data may have implications for our understanding of the
genesis of neurodevelopmental disorders of altered sociability. A
better understanding of the mechanisms underlying these social
deﬁcits, which may include modulation of immune cell cytokines
release, changes in vagal nerve activity and neuroendocrine
function, could potentially lead to the emergence of novel and
more effective therapies to combat symptoms in the social domain.
Figure 1. Effects of germ-free (GF) rearing and germ-free bacterial colonisation (GFC) on social behaviours in male mice. In the three-
chambered sociability test, GF mice failed to show the normal preference for the social chamber displayed by conventionally colonised (CC)
and GFC groups during trial 2, as seen in the automated tracking images (a), the time spent in each chamber (b) and the difference between
time spent in mouse and empty chambers (c). This social avoidance was reversed in GFC mice (b and c). GF and GFC mice also failed to show
normal preference for social novelty displayed by CC mice during trial 3, as seen in the automated tracking images (d), the time spent in each
chamber (e) and the difference between time spent in the chambers containing a novel and familiar mouse (f ). In the social transmission of
food preference test, GF rearing conditions altered social investigation time (g) and grooming time (h) during social interaction
with demonstrator mice. There was no effect on the preference for cued food immediately after social interaction (i) and 24 h later (j).
Po0.01, Po0.001 versus opposite chamber; repeated-measures analysis of variance followed by post-hoc Newman–Keuls test (n¼ 713);
*Po0.05, ***Po0.001 versus CC; #Po0.01, ##Po0.001 versus GF; one-way analysis of variance followed by post-hoc Newman–Keuls
test (n¼ 5–13).
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New research and clinical criteria for Alzheimer’s disease (AD) have
recently been proposed, which include biomarker information on
Alzheimer’s plaque and tangle pathology, or AD-typical structural
brain changes, as supporting or essential elements of an AD
diagnosis.1–3 In a large group of patients with both genetic and
cerebrospinal ﬂuid (CSF) biomarker data, we here show that
biomarker-assisted diagnosis-making almost doubles the effect
size of the association between the e4 variant of the
apolipoprotein E (APOE) gene and AD.
We included clinically diagnosed patients with either AD
dementia (n¼ 309) or mild cognitive impairment (MCI) due to AD
(n¼ 287), cognitively normal controls (n¼ 251) and patients with
MCI who remained stable over at least 2 years (n¼ 399) or
developed dementias other than AD (n¼ 99) (Table 1, Supplemen-
tary Material). All had APOE e2/e3/e4 genotypes and results on the
CSF biomarkers total tau (T-tau), phosphorylated tau (P-tau) and the
42-amino-acid isoform of amyloid-b (Ab42) determined. These CSF
biomarkers reﬂect the core elements of Alzheimer’s pathology4
and are strongly associated with AD in cross-sectional as well as
longitudinal follow-up studies (Supplementary Material).5,6
AD dementia and MCI-AD patients were ﬁrst pooled into one
clinical AD group (n¼ 596) and compared with all remaining
categories that were designated non-AD (n¼ 749). A positive
APOE e4 carrier status (one or two e4 alleles) was overrepresented
in the AD group and yielded an odds ratio (OR) of 4.45 (95%
conﬁdence interval (CI) 3.52–5.62) for a clinical diagnosis of AD at
inclusion or follow-up (Figure 1). This OR is similar to the AlzGene
meta-analysis of APOE (3.68, 95% CI 3.30–4.11, www.alzgene.org/
meta.asp?geneID=83, November 2012 freeze). Similarly, we tested
the association of APOE e4 with AD, comparing the 596 AD
patients with the 251 cognitively normal controls, which resulted
in an OR of 6.35 (95% CI 4.59–8.80).
Disregarding the clinical diagnoses and subgrouping all
subjects into amyloid-positive, deﬁned as CSF Ab42 o546 ng l 1
(n¼ 779), and amyloid-negative, deﬁned as CSF Ab42
X546 ng l 1 (n¼ 563) (see Supplementary Material for details
on cut-point determination), gave an OR for APOE e4 as high as
Figure 1. Odds ratios for a positive APOE e4 carrier status based on
(A) clinical diagnosis, comparing patients with clinical AD with
dementia at inclusion or follow-up (n¼ 596) versus all other
diagnostic groups (n¼ 749), (B) clinical diagnosis, comparing
patients with clinical AD with dementia at inclusion or follow-up
(n¼ 596) with cognitively normal subjects (n¼ 251), (C) CSF Ab42,
comparing subjects with CSF Ab42 below (n¼ 779) and above
(n¼ 563) 546 ng/l, (D) CSF T-tau, comparing subjects with CSF T-tau
above (n¼ 676) and below (n¼ 662) 446 ng/l, (E) CSF P-tau,
comparing subjects with CSF P-tau above (n¼ 497) and below
(n¼ 759) 79 ng/l, (F) CSF P-tau/Ab42 ratio, comparing subjects with
CSF P-tau/Ab42 above and below 0.15, (G) CSF biomarker signatures,
comparing subjects with an AD-indicative CSF signature with
regards to all three biomarkers T-tau, P-tau and Ab42, and subjects
with a normal complete profile (cut-points specified above) and (H)
CSF biomarker signatures in addition to clinical diagnosis, compar-
ing patients with clinical AD and an AD-indicative CSF biomarker
signature versus cognitively normal subjects with normal CSF
biomarker results (cut-points specified above). Note that columns
C-G are derived without any clinical information.
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